A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Crenigacestat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly
- 19 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Mar 2018.
- 17 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History